Trials (May 2022)

Statistical analysis plan for the randomized controlled trial Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST)

  • Agnethe Eltoft,
  • Tom Wilsgaard,
  • Melinda B. Roaldsen,
  • Mary-Helen Søyland,
  • Erik Lundström,
  • Jesper Petersson,
  • Bent Indredavik,
  • Jukka Putaala,
  • Hanne Christensen,
  • Janika Kõrv,
  • Dalius Jatužis,
  • Stefan T. Engelter,
  • Gian Marco De Marchis,
  • David J. Werring,
  • Thompson Robinson,
  • Arnstein Tveiten,
  • Ellisiv B. Mathiesen

DOI
https://doi.org/10.1186/s13063-022-06301-0
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background Patients with wake-up ischemic stroke are frequently excluded from thrombolytic treatment due to unknown symptom onset time and limited availability of advanced imaging modalities. The Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST) is a randomized controlled trial of intravenous tenecteplase 0.25 mg/kg and standard care versus standard care alone (no thrombolysis) in patients who wake up with acute ischemic stroke and can be treated within 4.5 h of wakening based on non-contrast CT findings. Objective To publish the detailed statistical analysis plan for TWIST prior to unblinding. Methods The TWIST statistical analysis plan is consistent with the Consolidating Standard of Reporting Trials (CONSORT) statement and provides clear and open reporting. Discussion Publication of the statistical analysis plan serves to reduce potential trial reporting bias and clearly outlines the pre-specified analyses. Trial registration ClinicalTrials.gov NCT03181360 . EudraCT Number 2014-000096-80 . WHO ICRTP registry number ISRCTN10601890 .

Keywords